Landau In Der Pfalz

Researchers are studying how personalized cognitive-behavioral therapy CBT compares to standardized CBT for treating chronic primary pain CPP, a condition where pain lasts for at least six months and is the main symptom. This study aims to see if tailoring CBT using data-driven methods can improve treatment outcomes compared to a standard approach. The study involves adult patients with CPP from German outpatient clinics and includes detailed measurement of pain disability, treatment expectations, and side effects. Participants receive both personalized and standardized CBT in different orders. Personalized CBT uses data from a 21-day ecological momentary assessment EMA to create individual treatment targets and deliver one of ten specialized therapy modules. Standardized CBT follows a manual with five core sessions including techniques like relaxation and cognitive strategies. The study includes a diagnostic phase, two treatment phases, baselines between treatments, and a 3-week EMA phase, plus two booster sessions at one and three months post-therapy. During the study, participants complete questionnaires on pain disability, disability in daily life, therapeutic alliance, treatment expectations, side effects, and pain intensity at multiple points from baseline through follow-up up to six months later. Data are collected before and after each phase and frequently during treatment. Researchers analyze both group-level and individual changes to understand therapy effects and aim to enroll 75 participants to ensure reliable results.

Researchers are evaluating the effectiveness and safety of a subcutaneous treatment using one cycle of cladribine for patients with hairy cell leukemia who need treatment. This study focuses on patients who are either untreated or have been previously treated only with alpha-interferon. The goal is to determine the rate of complete remission and to assess whether a second cycle of treatment benefits those with a non-optimal response, defined as detectable residual disease or partial remission four months after the initial treatment. Participants receive cladribine at a dose of 0.14 mgkg body weight administered subcutaneously as a bolus injection once daily for five consecutive days. After four months, remission status is evaluated. Patients showing non-optimal response may be considered for a second treatment cycle. This phase 23 trial is designed to optimize therapy for hairy cell leukemia by closely monitoring treatment response and toxicity. During the study, participants undergo evaluations including disease status assessment through bone marrow and blood tests, with a focus on remission rates four months post-treatment. Researchers track complete remission rates and monitor for residual disease. Safety is also monitored by assessing potential toxicities. Participants general health status and other laboratory tests are reviewed to ensure eligibility and ongoing suitability for treatment throughout the study period, which spans several months with follow-up assessments.